PEDIATRICS Vol. 66 No. 3 September 1980, pp. 484
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J. C. M.
Right arrow Articles by Bartter, F. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chan, J. C. M.
Right arrow Articles by Bartter, F. C.

Letters to the Editor

James C. M. Chan MD1 and Frederic C. Bartter MD2

1 Medical College of Virginia, Richmond, VA 23298
2 Veterans Administration Hospital, University of Texas, Health Science Center at San Antonio, San Antonio, TX 78284

In the treatment of renal hypophosphatemic rickets, the risks of hypercalcemia and vitamin D toxicity are always imminent. The use of 1,25-dihydroxyvitamin D with its shorter half-life offers a distinct advantage in conjunction with the continuous phosphate supplementation.1-3

The accelerated growth velocity secondary to the use of 1,25-dihydroxyvitamin D has now been extended to five patients. The initial report in a 3-year-old girl2 showed acceleration of growth velocity from the 25th to the 78th percentile.